keyword
MENU ▼
Read by QxMD icon Read
search

oral oncology

keyword
https://www.readbyqxmd.com/read/29441498/cost-of-illness-of-japanese-patients-with-chronic-lymphocytic-leukemia-cll-and-budget-impact-of-the-market-introduction-of-ibrutinib
#1
Jörg Mahlich, Shinichiro Okamoto, Akiko Tsubota
BACKGROUND: Ibrutinib was introduced in Japan in 2016 as a new oral treatment option for patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). There is increasing interest from the Japanese government to assess economic aspects of new medical interventions, especially in the area of oncology. OBJECTIVE: We describe the treatment patterns of Japanese patients with CLL, estimate the cost of the disease from a health insurance perspective, and predict the budget impact of the introduction of ibrutinib...
September 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29439857/axitinib-in-combination-with-pembrolizumab-in-patients-with-advanced-renal-cell-cancer-a-non-randomised-open-label-dose-finding-and-dose-expansion-phase-1b-trial
#2
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi, Brad Rosbrook, Kathrine C Fernandez, Mariajose Lechuga, Toni K Choueiri
BACKGROUND: Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective VEGF inhibitor than others previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield antitumour activity in patients with treatment-naive advanced renal cell carcinoma. METHODS: In this ongoing, open-label, phase 1b study, which was done at ten centres in the USA, we enrolled patients aged 18 years or older who had advanced renal cell carcinoma (predominantly clear cell subtype) with their primary tumour resected, and at least one measureable lesion, Eastern Cooperative Oncology Group performance status 0-1, controlled hypertension, and no previous systemic therapy for renal cell carcinoma...
February 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29438463/efficacy-and-safety-findings-from-dream-a-phase-iii-study-of-dhp107-oral-paclitaxel-versus-iv-paclitaxel-in-patients-with-advanced-gastric-cancer-after-failure-of-first-line-chemotherapy
#3
Y-K Kang, M-H Ryu, S H Park, J G Kim, J W Kim, S-H Cho, Y-L Park, S R Park, S Y Rha, M J Kang, J Y Cho, S Y Kang, S Y Roh, B-Y Ryoo, B-H Nam, Y-W Jo, K-E Yoon, S C Oh
Background: Paclitaxel is currently only available as an intravenous (IV) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to IV paclitaxel as second-line therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29438178/treatment-of-pancreatic-cancer-with-intravenous-vitamin-c-a-case-report
#4
Jeanne A Drisko, Oscar K Serrano, Lisa R Spruce, Qi Chen, Mark Levine
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a considerable financial burden. As a result, some patients turn to integrative medicine therapies as an alternate option after a diagnosis of PDA. Intravenous pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has been passionately debated for many years, but more recent rigorous scientific research has shown that there are significant blood concentration differences when ascorbic acid is given parenterally when compared to oral dosing...
February 12, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29437041/preoperative-exercise-halves-the-postoperative-complication-rate-in-patients-with-lung-cancer-a-systematic-review-of-the-effect-of-exercise-on-complications-length-of-stay-and-quality-of-life-in-patients-with-cancer
#5
REVIEW
Daniel Steffens, Paula R Beckenkamp, Mark Hancock, Michael Solomon, Jane Young
OBJECTIVE: To investigate the effectiveness of preoperative exercises interventions in patients undergoing oncological surgery, on postoperative complications, length of hospital stay and quality of life. DESIGN: Intervention systematic review with meta-analysis. DATA SOURCES: MEDLINE, Embase and PEDro. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Trials investigating the effectiveness of preoperative exercise for any oncological patient undergoing surgery were included...
February 1, 2018: British Journal of Sports Medicine
https://www.readbyqxmd.com/read/29435836/oral-and-dental-health-in-head-and-neck-cancer-patients
#6
Joel B Epstein, Andrei Barasch
A diagnosis of head and neck cancer (HNC) is typically followed by therapy that is associated with immediate and long-lasting toxic consequences. HNC patients' oral health needs may be complex and are best addressed in multidisciplinary collaborative teams including surgical, medical, and radiation oncologists, dental providers, nutrition, speech/swallow specialists, and physical therapists. Oral health maintenance also requires patient compliance and caregiver support. The role of dental providers begins prior to cancer diagnosis and continues through survivorship...
2018: Cancer Treatment and Research
https://www.readbyqxmd.com/read/29433850/lenvatinib-versus-sorafenib-in-first-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-a-randomised-phase-3-non-inferiority-trial
#7
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem, Jean Frederic Blanc, Arndt Vogel, Dmitry Komov, T R Jeffry Evans, Carlos Lopez, Corina Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann-Lii Cheng
BACKGROUND: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. METHODS: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions...
February 9, 2018: Lancet
https://www.readbyqxmd.com/read/29423682/locally-advanced-oral-squamous-cell-carcinoma-patients-treated-with-photobiomodulation-for-prevention-of-oral-mucositis-retrospective-outcomes-and-safety-analyses
#8
Thaís Bianca Brandão, Karina Morais-Faria, Ana Carolina Prado Ribeiro, César Rivera, João Victor Salvajoli, Marcio Ajudarte Lopes, Joel B Epstein, Praveen R Arany, Gilberto de Castro, Cesar Augusto Migliorati, Alan Roger Santos-Silva
PURPOSE: The well-established clinical efficacy of photobiomodulation (PBM) therapy in management of oral mucositis (OM) is leading to increasing use in oncology care. This protection and enhanced repair of damage to mucosal tissue have led to the question of the potential effects of PBM therapy on pre-malignant and malignant cells. The purpose of this study was to examine the outcome of cancer therapy and incidence of tumor recurrence in locally advanced oral squamous cell carcinoma (OSCC) patients treated with PBM therapy for OM...
February 8, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29418009/multidisciplinary-approach-in-a-case-of-hand-sch%C3%A3-ller-christian-disease-with-maxillary-involvement
#9
Angela Pia Cazzolla, Nunzio Francesco Testa, Gianfranco Favia, Maria Grazia Lacaita, Domenico Ciavarella, Khrystyna Zhurakivska, Giuseppe Troiano, Lorenzo Lo Muzio
Langerhans cell histiocytosis (LCH) is a childhood pathology with a peak of incidence ranging from 1 to 4 years of age, though diagnosis is often made in adult age. LCH is clinically classified into three types: eosinophilic granuloma, Hand-Schuller-Christian disease and Abt-Letterer-Siwe disease. We report a case of Hand-Schüller-Christian disease with diabetes insipidus, skull and maxillary involvement in a 16-year-old boy referred to our observation for gradual increase in mobility of the teeth and subsequent gradual loss of the second premolars and the first molars of the upper jaw...
February 8, 2018: Special Care in Dentistry
https://www.readbyqxmd.com/read/29413278/multicenter-study-of-carbon-ion-radiation-therapy-for-adenoid-cystic-carcinoma-of-the-head-and-neck-subanalysis-of-the-japan-carbon-ion-radiation-oncology-study-group-j-cros-study-1402-hn
#10
Nor Shazrina Sulaiman, Yusuke Demizu, Masashi Koto, Jun-Ichi Saitoh, Hiroaki Suefuji, Hiroshi Tsuji, Tatsuya Ohno, Yoshiyuki Shioyama, Tomoaki Okimoto, Takashi Daimon, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
PURPOSE: To retrospectively analyze the treatment outcomes of carbon-ion radiation therapy for adenoid cystic carcinoma (ACC) of the head and neck at 4 active carbon-ion facilities in Japan. METHODS AND MATERIALS: A total of 289 patients who underwent carbon-ion radiation therapy for histology-proven ACC of the head and neck at 4 institutions in Japan between November 2003 and December 2014 were included in this study. RESULTS: Median patient age was 58 years (range, 12-83 years)...
March 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29413057/tumor-biomarker-testing-in-non-small-cell-lung-cancer-a-decade-of-change
#11
Paul A VanderLaan, Deepa Rangachari, Adnan Majid, Mihir S Parikh, Sidharta P Gangadharan, Michael S Kent, Danielle C McDonald, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa
INTRODUCTION: Although a growing list of essential genomic/immune-based biomarkers are linked to approved non-small-cell lung cancer (NSCLC) therapies worldwide, few reports have detailed the evolution of NSCLC predictive biomarker assessment in routine clinical practice. METHODS: We retrospectively reviewed the first one thousand plus NSCLC patient specimens from our institution analyzed for predictive biomarkers from 2004 to 2017 and evaluated patterns of testing as well as correlation with clinical-pathologic characteristics...
February 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29397354/napabucasin-versus-placebo-in-refractory-advanced-colorectal-cancer-a-randomised-phase-3-trial
#12
Derek J Jonker, Louise Nott, Takayuki Yoshino, Sharlene Gill, Jeremy Shapiro, Atsushi Ohtsu, John Zalcberg, Michael M Vickers, Alice C Wei, Yuan Gao, Niall C Tebbutt, Ben Markman, Timothy Price, Taito Esaki, Sheryl Koski, Matthew Hitron, Wei Li, Youzhi Li, Nadine M Magoski, Chiang J Li, John Simes, Dongsheng Tu, Christopher J O'Callaghan
BACKGROUND: Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in advanced colorectal cancer. METHODS: This study was a double-blind randomised phase 3 trial done at 68 centres in Canada, Australia, New Zealand, and Japan. Patients with advanced colorectal cancer with a good Eastern Cooperative Oncology Group (ECOG) performance status (0-1) for whom all available standard therapies had failed were eligible for the study...
January 31, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29396091/ibrutinib-lenalidomide-and-rituximab-in-relapsed-or-refractory-mantle-cell-lymphoma-philemon-a-multicentre-open-label-single-arm-phase-2-trial
#13
Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad
BACKGROUND: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing regimen, an Eastern Cooperative Oncology Group performance status score of 0-3, and at least one site of measurable disease, and who met criteria for several laboratory-assessed parameters...
January 29, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29390253/factors-associated-with-acute-oral-mucosal-reaction-induced-by-radiotherapy-in-head-and-neck-squamous-cell-carcinoma-a-retrospective-single-center-experience
#14
Zhenchao Tao, Jin Gao, Liting Qian, Yifan Huang, Yan Zhou, Liping Yang, Jian He, Jing Yang, Ru Wang, Yangyang Zhang
To investigate risk factors for acute oral mucosal reaction during head and neck squamous cell carcinoma radiotherapy.A retrospective study of patients with head and neck squamous cell carcinoma who underwent radiotherapy from November 2013 to May 2016 in Anhui Provincial Cancer Hospital was conducted. Data on the occurrence and severity of acute oral mucositis were extracted from clinical records. Based on the Radiation Therapy Oncology Group (RTOG) grading of acute radiation mucosal injury, the patients were assigned into acute reaction (grades 2-4) and minimum reaction (grades 0-1) groups...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29389441/oral-head-and-neck-oncologic-and-reconstructive-surgery-the-creation-of-a-subspecialty-in-oral-and-maxillofacial-surgery
#15
Eric R Carlson
No abstract text is available yet for this article.
February 2018: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/29389333/targeted-cancer-therapies-oral-health-care-implications
#16
Eleni Georgakopoulou, Justin Stebbing, Crispian Scully
BACKGROUND: Targeted treatments have been incorporated into oncology protocols, often with more traditional therapies, and are not totally free of adverse reactions, some of which affect the orofacial region. METHODS: The authors searched PubMed, the Cochrane Library, and the US Food and Drug Administration Approved Drug Products database to identify reported adverse effects of targeted agents in the orofacial region as well as other implications in oral health care...
February 2018: Journal of the American Dental Association
https://www.readbyqxmd.com/read/29383509/oral-health-impact-profile-of-head-and-neck-cancer-patients-after-or-before-oncologic-treatment-an-observational-analytic-case-control-study
#17
Vitor T Stuani, Paulo Sérgio S Santos, Carla A Damante, Mariana S R Zangrando, Sebastião Luiz A Greghi, Maria Lúcia R Rezende, Adriana C P Sant'Ana
PURPOSE: The objective of this study was to investigate the impact of oral health on the quality of life of patients with head and neck cancer (HNC) before and after oncologic treatment. METHODS: Forty cancer-free individuals (Cf group) and 40 HNC patients (Hnc group) were included in this study. Hnc group was also divided into two subgroups: Hnc 1 (pre-cancer therapy, n = 20) and Hnc 2 (post-cancer therapy, n = 20). Participants were asked to complete a short form of Oral Health Impact Profile (OHIP-14)...
January 30, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29382990/clinical-spectrum-treatment-and-relapse-patterns-in-353-patients-with-squamous-cell-carcinoma-of-the-alveobuccal-complex-treated-with-a-curative-intent-a-retrospective-study
#18
Nootan Kumar Shukla, S V Suryanarayana Deo, Ashish Jakhetiya, Manjunath Nml, Vishnubhatla Sreenivas, Sanjay Thulkar, Suman Bhasker, Atul Sharma
Aims and Objectives: Oral cancer is one of the most common cancers in Indian subcontinent with alveobuccal complex as most common cancer sub site. Cancers of Alveobuccal complex provides maximum challenge and management guidelines are not clear. The aim of the present study is to provide comprehensive demographic, clinical and treatment outcome data of alveobuccal squamous cell carcinoma (SCC) patients treated at a tertiary care cancer center in North India. Materials and Methods: An analysis of prospectively maintained database in department of surgical oncology at Dr BRA-IRCH, AIIMS, Delhi, India was performed...
March 2018: Journal of Maxillofacial and Oral Surgery
https://www.readbyqxmd.com/read/29378419/clinical-importance-of-eflornithine-%C3%AE-difluoromethylornithine-for-the-treatment-of-malignant-gliomas
#19
Victor A Levin, Sandra E Ictech, Kenneth R Hess
This review covers the literature between 1989 and 2007 on studies relevant to the neuro-oncology usage of eflornithine (α-difluoromethylornithine), an oral agent that irreversibly inhibits the enzyme ornithine decarboxylase. It covers the use of eflornithine, alone or in combination, to treat high-grade gliomas. In addition, we provide an update on overall survival from The University of Texas MD Anderson Cancer Center Community Clinical Oncology Program and Clinical Trials Data Office that demonstrates a meaningful benefit in overall survival for eflornithine as a single agent and in combination with nitrosourea-based therapies for anaplastic gliomas...
January 30, 2018: CNS Oncology
https://www.readbyqxmd.com/read/29377364/a-multicenter-randomized-controlled-trial-of-s-1-monotherapy-versus-s-1-and-interferon-%C3%AE-combination-therapy-for-hepatocellular-carcinoma-with-extrahepatic-metastases
#20
Hiroaki Nagano, Shuntaro Obi, Etsuro Hatano, Shuichi Kaneko, Fumihiko Kanai, Masao Omata, Akihito Tsuji, Toshiyuki Itamoto, Kazuhide Yamamoto, Masatoshi Tanaka, Shoji Kubo, Koichi Hirata, Hideji Nakamura, Yoshito Tomimaru, Takeharu Yamanaka, Shinsuke Kojima, Morito Monden
BACKGROUND: No effective therapies for extrahepatic metastases from hepatocellular carcinoma (HCC) have yet been identified. Previous studies suggested a potentially promising anti-tumor effect of combination therapy of S-1, a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitor, and interferon (IFN)-α. The present study aimed to investigate the clinical efficacy of single agent S-1 and S-1/IFN-α for HCC patients with extrahepatic metastases in a randomized, open-label, multicenter trial...
January 27, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
keyword
keyword
91223
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"